Opening the door to the development of novel Abl kinase inhibitors
The discovery of the importance of kinase activity and its relationship to the emergence and proliferation of cancer cells, due to changes in normal physiology, opened a remarkable pathway for the treatment of chronic myelogenous leukemia through intense search of drug candidates. Six Abl kinase inhibitors have received the US FDA approval as chronic myelogenous leukemia treatment, and continuous efforts in obtaining new, more effective and selective molecules are being carried out. Herein we discuss the mechanisms of Abl inhibition, structural features and ligand/protein interactions that are important for the design of new Abl kinase inhibitors. This review provides a broad overview of binding mode predictions, through molecular docking, which can be an approach to discover novel Abl kinase inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 8(2016), 17 vom: 15. Nov., Seite 2143-2165 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bezerra Morais, Pedro Alves [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4155/fmc-2016-0155 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM265594502 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM265594502 | ||
| 003 | DE-627 | ||
| 005 | 20231224212627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2016-0155 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0885.xml |
| 035 | |a (DE-627)NLM265594502 | ||
| 035 | |a (NLM)27774798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bezerra Morais, Pedro Alves |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Opening the door to the development of novel Abl kinase inhibitors |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The discovery of the importance of kinase activity and its relationship to the emergence and proliferation of cancer cells, due to changes in normal physiology, opened a remarkable pathway for the treatment of chronic myelogenous leukemia through intense search of drug candidates. Six Abl kinase inhibitors have received the US FDA approval as chronic myelogenous leukemia treatment, and continuous efforts in obtaining new, more effective and selective molecules are being carried out. Herein we discuss the mechanisms of Abl inhibition, structural features and ligand/protein interactions that are important for the design of new Abl kinase inhibitors. This review provides a broad overview of binding mode predictions, through molecular docking, which can be an approach to discover novel Abl kinase inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bio-organic chemistry | |
| 650 | 4 | |a chronic myelogenous leukemia | |
| 650 | 4 | |a computational chemistry and molecular modeling | |
| 650 | 4 | |a drug design | |
| 650 | 4 | |a drug development | |
| 650 | 4 | |a molecular biology | |
| 650 | 4 | |a oncological therapeutics | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a protein chemistry | |
| 650 | 4 | |a structural biology | |
| 700 | 1 | |a Daltoé, Renata Dalmaschio |e verfasserin |4 aut | |
| 700 | 1 | |a Paula, Heberth de |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 8(2016), 17 vom: 15. Nov., Seite 2143-2165 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2016 |g number:17 |g day:15 |g month:11 |g pages:2143-2165 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2016-0155 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2016 |e 17 |b 15 |c 11 |h 2143-2165 | ||